Palo Alto, Calif.-based Atropos Health, a company translating real-world clinical data into real-world evidence for decision-making, announced it is partnering with Merck to generate RWE, replicate studies, and produce rapid insights and analytics on real-world data. 

Via the partnership, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours.  

Merck’s data science and RWE teams will employ Atropos Health services, including GENEVA OS (Generative Evidence Acceleration Operating System), Green Button, Atropos Evidence Network and Alexandria, Forge and ChatRWD.  

Additionally, Merck teams will work closely with Atropos Health’s data scientists, technologists and researchers to produce rapid analytics and evidence generation.

"Global life sciences organizations are relying on RWE for decision-making when it comes to the innovation of life-saving treatments," Brigham Hyde, CEO and cofounder of Atropos Health, told MobiHealthNews. 

"With the Atropos Health platform, Merck can now leverage automation and rapid evidence generation into their development of new treatments."

 THE LARGER TREND

In 2024, Atropos secured $33 million in Series B funding. Valtruis led the investment round, which included new investors McKesson Ventures, Merck GHI Fund and Cencora Ventures. Emerson Collective, Breyer Capital and Presidio Ventures also participated in the round.

That same year, Atropos announced that Arcadia joined its health portfolio, giving Arcadia's provider customers and life sciences users access to Atropos' offerings. Through the partnership, Arcadia joined Atropos' Evidence Network, allowing its users access to Atropos' portfolio of applications to support clinical decision-making in value-based care. 

In 2022, life science firm Merck Korea and Standigm, a South Korea-based AI drug discovery company signed a memorandum of understanding for AI-driven drug-discovery research. The partnership involved Standigm's adoption of Merck's AI software SYNTHIA for compound synthesis.

Merck also joined forces that year with Israel-based AION Labs on the creation of a new AI-focused platform designed to help pharma research.